{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T05:04:03Z","timestamp":1789535043402,"version":"build-2803163510"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>In 2020, Oregon became the first US state to legalize state-regulated psilocybin services. This study aims to examine: (1) the clinical and demographic characteristics, (2) psilocybin use motivations, and (3) differences in preparedness among patients seeking care in an Oregon-based pilot consult service specializing in psilocybin risk reduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This exploratory retrospective chart review abstracted sociodemographics, trauma history, and medical and psychiatric risks of patients (November 2023\u2013September 2025). The Psychedelic Preparedness Scale (PPS), a validated self-report questionnaire, measured preparedness. Two sample\n                      <jats:italic>t<\/jats:italic>\n                      -tests examined associations of PPS scores by insurance, consult motivations, and prior psychedelic use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patients (\n                      <jats:italic>N<\/jats:italic>\n                      \u202f=\u202f29) had a mean age of 47.14\u202fyears (SD\u202f=\u202f15.9), were majority female (55.2%); White (82.8%); and privately insured (62.1%). Patients mostly sought psilocybin to address only a psychiatric concern (75.9%); 27.6% anticipated naturalistic (non-state regulated) use. Most patients were deemed low risk for adverse events. Prevalence of prior challenging psychedelic experiences (CPE) was 17.2%; 58.6% reported lifetime psilocybin use. 86.2% endorsed \u22651 form of lifetime trauma. Of PPS completers (\n                      <jats:italic>N<\/jats:italic>\n                      \u202f=\u202f23, 79%), mean score was 91.3 (SD\u202f=\u202f23.99). Scores did not significantly differ by insurance; consultation motivation; CPE; prior psilocybin or psychedelic use.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients utilizing a novel consultation service demonstrate a high prevalence of trauma, prior psilocybin use, and baseline preparedness. While preliminary, this study is among the first describing patients seeking medical and psychiatric consultation when considering psilocybin and highlights potential roles of healthcare systems in providing evidence-based patient education and risk reduction as interest in psychedelics grows.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1921031","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:29:01Z","timestamp":1789532941000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation service"],"prefix":"10.3389","volume":"14","author":[{"given":"Harland V.","family":"Harrison","sequence":"first","affiliation":[{"name":"School of Medicine, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizan","family":"Gaillard","sequence":"additional","affiliation":[{"name":"School of Medicine, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan R.","family":"Cook","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Geriatrics, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Sarparast","sequence":"additional","affiliation":[{"name":"School of Medicine, Oregon Health and Science University","place":["Portland, OR, United States"]},{"name":"Department of Psychiatry, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ximena A.","family":"Levander","sequence":"additional","affiliation":[{"name":"Division of General Internal Medicine and Geriatrics, Oregon Health and Science University","place":["Portland, OR, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"100454","DOI":"10.1016\/j.abrep.2022.100454","article-title":"Use of plant-based hallucinogens and dissociative agents: U.S. time trends, 2002-2019","volume":"16","author":"Walsh","year":"2022","journal-title":"Addict Behav Rep"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/02791072.2024.2401977","article-title":"The epidemiology of psychedelic use among United States military veterans","author":"Davis","year":"2024","journal-title":"J Psychoactive Drugs"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"104507","DOI":"10.1016\/j.drugpo.2024.104507","article-title":"The global psychedelic survey: consumer characteristics, patterns of use, and access in primarily anglophone regions around the world","volume":"130","author":"Lake","year":"2024","journal-title":"Int J Drug Policy"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.7326\/ANNALS-24-03145","article-title":"The rise of psilocybin use in the United States: a multisource observational study","volume":"178","author":"Rockhill","year":"2025","journal-title":"Ann Intern Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2147\/DDDT.S443177","article-title":"The promise of therapeutic psilocybin: an evaluation of the 134 clinical trials, 54 potential indications, and 0 marketing approvals on ClinicalTrials.gov","volume":"18","author":"Norring","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"120882","DOI":"10.1016\/j.jad.2025.120882","article-title":"Breaking the chains of depression: a systematic review and meta-analysis of psilocybin therapy","volume":"397","author":"Khan","year":"2026","journal-title":"J Affect Disord"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1192\/bjo.2025.10974","article-title":"Trends in the psychedelic renaissance: applying artificial intelligence to measure media portrayal of psychedelic drugs in the 21st century","volume":"12","author":"Bender","year":"2026","journal-title":"BJPsych Open"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.annemergmed.2023.11.003","article-title":"The rise of psychedelic drug use associated with legalization\/decriminalization: an assessment with the nonmedical use of prescription drugs survey","volume":"83","author":"Monte","year":"2024","journal-title":"Ann Emerg Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/02791072.2025.2454474","article-title":"Oregon\u2019s emerging psilocybin services workforce: a survey of the first legal psilocybin facilitators and their training programs","volume":"58","author":"Luoma","year":"2025","journal-title":"J Psychoactive Drugs"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1001\/jamapsychiatry.2022.4101","article-title":"Psychedelics drug legislative reform ant legalization in the US","volume":"80","author":"Siegel","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"ref11","volume-title":"Oregon Psilocybin Services - Data Archive: Prevention and Wellness: State of Oregon","year":""},{"key":"ref12","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1177\/02698811241257839","article-title":"Developing the open psychedelic evaluation Nexus consensus measures for assessment of supervised psilocybin services: an e-Delphi study","volume":"38","author":"Korthuis","year":"2024","journal-title":"J Psychopharmacol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e2630608","DOI":"10.1001\/jamanetworkopen.2026.30608","article-title":"Safety and mental health outcomes of Oregon state-regulated psilocybin services","volume":"9","author":"Korthuis","year":"2026","journal-title":"JAMA Netw Open"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1038\/s44161-025-00608-2","article-title":"Cardiovascular effects and safety of classic psychedelics","volume":"4","author":"Nahlawi","year":"2025","journal-title":"Nat Cardiovasc Res"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1007\/s00213-022-06083-y","article-title":"Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review","volume":"239","author":"Sarparast","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1038\/s41380-024-02800-5","article-title":"Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies","volume":"30","author":"Sab\u00e9","year":"2025","journal-title":"Mol Psychiatry"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/02698811231211219","article-title":"Drug\u2013drug interactions involving classic psychedelics: a systematic review","volume":"38","author":"Halman","year":"2024","journal-title":"J Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"100231","DOI":"10.1016\/j.acepjo.2025.100231","article-title":"US poison center encounters for psilocybin-related exposures: 2013-2022","volume":"6","author":"Montoy","year":"2025","journal-title":"J Am Coll Emerg Physicians Open"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1001\/jamapsychiatry.2025.3038","article-title":"Psilocybin outside the clinic: public health challenges of increasing publicity, accessibility, and use","volume":"83","author":"Hutchison","year":"2026","journal-title":"JAMA Psychiatry"},{"key":"ref20","volume-title":"Medical and Psychiatric Consultation for Patients Considering State-Regulated Psilocybin Services: A Risk-Reduction Model and Two Illustrative Cases (In Process)","author":"Sarvi","year":""},{"key":"ref21","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1038\/s41598-024-53829-z","article-title":"Development and psychometric validation of a novel scale for measuring \u2018psychedelic preparedness.\u2019","volume":"14","author":"McAlpine","year":"2024","journal-title":"Sci Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"780696","DOI":"10.3389\/fpsyt.2021.780696","article-title":"Psychedelic mushrooms in the USA: knowledge, patterns of use, and association with health outcomes","volume":"12","author":"Matzopoulos","year":"2022","journal-title":"Front Psych"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"105105","DOI":"10.1016\/j.drugpo.2025.105105","article-title":"Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences","volume":"148","author":"Olofsson","year":"2026","journal-title":"Int J Drug Policy"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"42852","DOI":"10.1038\/s41598-025-26198-4","article-title":"Recalled childhood trauma and post-psychedelic trajectories of change in a mixed-methods study","volume":"15","author":"Simon","year":"2025","journal-title":"Sci Rep"},{"key":"ref25","volume-title":"An Investigation Into the Varieties of Extended Difficulties Following Psychedelic Drug Use: Duration, Severity and Helpful Coping Strategies","author":"Robinson","year":"2024"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jad.2023.01.073","article-title":"Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics","volume":"326","author":"Simonsson","year":"2023","journal-title":"J Affect Disord"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e0293349","DOI":"10.1371\/journal.pone.0293349","article-title":"Extended difficulties following the use of psychedelic drugs: a mixed methods study","volume":"18","author":"Evans","year":"2023","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e30800","DOI":"10.1371\/journal.pone.0030800","article-title":"Prediction of psilocybin response in healthy volunteers","volume":"7","author":"Studerus","year":"2012","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/7854_2017_474","article-title":"Classic hallucinogens and mystical experiences: phenomenology and neural correlates","volume":"36","author":"Barrett","year":"2018","journal-title":"Curr Top Behav Neurosci"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.2147\/NDT.S426193","article-title":"Predicting the intensity of psychedelic-induced mystical and challenging experience in a healthy population: an exploratory post-hoc analysis","volume":"19","author":"Ko","year":"2023","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fphar.2018.00897","article-title":"Predicting responses to psychedelics: a prospective study","volume":"9","author":"Haijen","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1007\/s00213-021-06049-6","article-title":"Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research","volume":"239","author":"Bender","year":"2022","journal-title":"Psychopharmacology"},{"key":"ref33","first-page":"1","volume-title":"Ontologically Challenging Psychedelic Experiences: Considerations for Managing Associated Distress","author":"Argyri","year":""},{"key":"ref34","volume-title":"Navigating Psychedelic Experiences: Introducing the Psychedelic Preparedness Scale (PPS)","author":"Nature","year":"2024"},{"key":"ref35","volume-title":"AndriSignorell\/DescTools","author":"Signorell","year":"2026"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s44220-025-00417-3","article-title":"A systematic review of income and education reporting in psychedelic clinical trials","volume":"3","author":"Grossman","year":"2025","journal-title":"Nat Ment Health"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1017\/S0033291715001981","article-title":"The epidemiology of traumatic event exposure worldwide: results from the world mental health survey consortium","volume":"46","author":"Benjet","year":"2016","journal-title":"Psychol Med"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"20451253251342319","DOI":"10.1177\/20451253251342319","article-title":"Clinical conceptualisation of PTSD in psilocybin treatment: disrupting a pre-determined and over-determined maladaptive interpretive framework","volume":"15","author":"Modlin","year":"2025","journal-title":"Ther Adv Psychopharmacol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S0140-6736(10)61462-6","article-title":"Drug harms in the UK: a multicriteria decision analysis","volume":"376","author":"Nutt","year":"2010","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1177\/02698811231182012","article-title":"The New Zealand drug harms ranking study: a multi-criteria decision analysis","volume":"37","author":"Crossin","year":"2023","journal-title":"J Psychopharmacol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1177\/0269881116662634","article-title":"Survey study of challenging experiences after ingesting psilocybin mushrooms: acute and enduring positive and negative consequences","volume":"30","author":"Carbonaro","year":"2016","journal-title":"J Psychopharmacol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"645246","DOI":"10.3389\/fpsyg.2021.645246","article-title":"Psychedelic harm reduction and integration: a Transtheoretical model for clinical practice","volume":"12","author":"Gorman","year":"2021","journal-title":"Front Psychol"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"116359","DOI":"10.1016\/j.psychres.2025.116359","article-title":"A systematic review of participant diversity in psychedelic-assisted psychotherapy trials","volume":"345","author":"Haft","year":"2025","journal-title":"Psychiatry Res"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/02698811231180276","article-title":"Risk of bias in randomized clinical trials on psychedelic medicine: a systematic review","volume":"37","author":"Hovmand","year":"2023","journal-title":"J Psychopharmacol Oxf Engl"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1921031\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:29:03Z","timestamp":1789532943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1921031\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":44,"alternative-id":["10.3389\/fpubh.2026.1921031"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1921031","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1921031"}}